Table 1.
Baseline Demographic and Clinical Characteristics of the Study Patients
| Characteristic | Data (n=81) |
|---|---|
| Age (yrs) | 48.9 ± 9.3 |
| Years of education | 11.0 ± 3.4 |
| DHEAS level (μmol/L) | 1.61 ± 0.91 |
| DHEA level (nmol/L) | 19.21 ± 13.13 |
| Fatigue level scorea | 1.76 ± 1.69 |
| Anxiety level scoreb | 7.27 ± 6.38 |
| Insomnia scorec | 20.25 ± 25.82 |
| Ethnicity | |
| Chinese | 67 (82.7) |
| Malay | 9 (11.1) |
| Indian | 2 (2.5) |
| Other | 3 (3.7) |
| Breast cancer stage | |
| I | 14 (17.3) |
| II | 44 (54.3) |
| III | 23 (28.4) |
| ECOG performance status | |
| 0 | 74 (91.4) |
| 1 | 7 (8.6) |
| Chemotherapy regimen | |
| Anthracycline based | 54 (66.7) |
| Taxane based | 27 (33.3) |
| Menopausal status | |
| Premenopausal | 43 (53.1) |
| Postmenopausal | 38 (46.9) |
Data are mean ± SD values or no. (%) of patients.
DHEA = dehydroepiandrosterone; DHEAS = DHEA sulfate; ECOG = Eastern Cooperative Oncology Group.
a
The Brief Fatigue Inventory's total score is out of a maximum of 10 points, with a higher score indicating more severe fatigue.
b
The Beck Anxiety Inventory's total score is out of a maximum of 63 points, with a higher score indicating more severe anxiety.
c
The insomnia's subscale total score is out of a maximum of 100 points, with a higher score indicating more or worse symptoms.